Exploring the Role of PCSK9 Inhibitors in the
Reduction of LDL-C in Patients with Dyslipidemia

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 25, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by an educational grant from
Amgen Inc.

Current guidelines agree that LDL-C is a major factor in the development of cardiovascular disease (CVD). In addition, it is well established that lowering LDL-C in high-risk patients reduces the risk for CVD. The discovery of statins has contributed a very effective approach to help battle the irregular levels of LDL-C. However, many patients do not achieve the recommended goals for LDL-C levels. Available agents combined with statins can provide additional LDL-C reduction. In fact, genetic insights into the study of LDL-C levels have expanded potential targets of drug therapy and led to the development of novel therapeutic agents. Among them are modulators containing lipoproteins production and proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors. The mechanism of action of PCSK9 agents are different than that of widely-used statins which inhibit the liver's production of LDL cholesterol in the first place, and to which some patients don't respond well. The PCSK9, man-made antibodies, block a protein that prevents the body from eliminating LDL cholesterol from the bloodstream and offer a new way of fighting the build-up of artery-clogging fatty deposits. In earlier mid-stage studies, when combined with statins, alirocumab and the PCSK9 drug cut levels of LDL cholesterol by close to 70 percent, more than statins alone.

Upon Completion of this activity, participants will be able to:

  • Discuss updated guidelines and clinical evidence for new LDL-C lowering therapies, including their current and future role in managing dyslipidemia

  • Assess the safety, efficacy and mechanisms of action for emerging therapies to address dyslipidemia, including the evidence of PCKS9 inhibitors

  • Identify optimal strategies, including effective screening and diagnostic measures, to incorporate the latest treatment advances to help reduce cardiovascular risk

  • Analyze the updated clinical evidence on genetic mutations, biologics and their potential therapeutic significance in the development of novel agents

  • Evaluate the clinical data in relation to the benefits and roles of PCSK9 inhibitors in the treatment and management of dyslipidemia

Faculty: Michael Miller, MD, FACC, FAHA
Professor of Cardiovascular Medicine, Epidemiology & Public Health
University of Maryland School of Medicine
Staff Physician, Baltimore VAMC
Director, Center for Preventive Cardiology
University of Maryland Medical Center


Dr. Miller serves as the US National Coordinator for the SPIRE trial sponsored by Pfizer, on the Steering Committee for the REDUCE IT trial sponsored by Amarin and as US National Coordinator for the DalGene trial sponsored by Dalcor. His presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Jacquelyn Smith has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation

The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This educational activity is supported by an educational grant from
Amgen Inc.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue